ArticleAnnals of medicine2025
Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SARIFA and Lipid Metabolic Reprogramming in Prostate Cancer: Fundamental Mechanisms, Tumor Microenvironment, and Novel Biomarker Prospects.Life (Basel, Switzerland) · 2026Review
- Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop patient-derived organoids (PDOs) using biopsied tissue of primary prostate cancer (PCa).
methodsFresh tumour tissues of PCa were obtained from patients who underwent targeted biopsy in our centre for the culture of PDOs. Hematoxylin-Eosin (H & E) and immunohistochemical staining were used to determine the histology of the cultured PDOs, using the parental tumours as the reference. Whole exome sequencing (WES) was conducted to verify the genetic conservation of PDOs, using the parental tumours as the reference. Drug screening was carried out to test the feasibility of PDOs as preclinical models.
resultsH & E and immunohistochemical staining indicated similar pathologic features between our developed PDOs and the parental tumours. WES also demonstrated similar somatic mutations, base substitutions and copy number variations between PDOs and the parental tumours. Drug screening results showed heterogeneity of the cultured PDOs to enzalutamide, docetaxel, and olaparib.
conclusionPDOs can be successfully developed based on targeted biopsy of primary PCa, which may be an optimal preclinical model to predict treatment response in the era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.